Clinical trial · Observational
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors
NCT06780384CI-TRIAL-00084845NTRKactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the incidence of NTRK rearrangements in patients with solid tumors in Italy. Additionally, the study seeks to define the correlation between IHC and FISH testing and to simplify the assessment of NTRK rearrangements in patients with solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NTRK1/2/3 Fusion Gene Detection | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To assess the incidence of NTRK rearrangements in patients with solid tumors in Italy
- timeFrame
- 36 months
- description
- Tumor tissue slides (4 micron) will be tested for NTRK positivity by means of immunohistochemistry (IHC) and then confirmed by means of fluorescence in-situ hybridization (FISH).
Secondary outcomes (1)
- measure
- To define incidence of NTRK in different tumor types
- timeFrame
- 36 months
- description
- The incidence of NTRK gene fusions across different tumor types involves determining how frequently these genetic alterations occur within various malignancies. This process is essential for understanding the potential role of targeted therapies, such as TRK inhibitors, in specific cancers
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological diagnosis of any solid cancer * Availability of tumor tissue for biomarker analyses (at least 5 slides, 4 micron) * Signed informed consent form Exclusion Criteria: * No tumor tissue available
References
Publications (0)
Data not yet available
No reference posted for this study.